Medicilon

🎄 Season's Greetings from Medicilon! 🎉 #MerryChristmas #HappyNewYear #MedicilonUSA #BiotechInnovation #HolidayGreetings

📷Medicilon Taiwan Workshop📷 📷New Approaches to Facilitate Drug Discovery and Development 📷 Learn More About Our Services: medicilon.com/services/

Medicilon Supports Jemincare's JMX-2002 Liposome Injection Clinical Trial Approval medicilon.com/cases/jmx-2002/

🚀Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres JM045 is a GnRH analog designed for prostate cancer. Medicilon provided pharmacokinetic studies and GLP-compliant safety evaluations. 👇 medicilon.com/cases/jm045/

HRS-9563, a cutting-edge siRNA Class I drug, has been approved for the treatment of hypertension. Medicilon provided vital preclinical pharmacokinetics studies and GLP-compliant safety evaluations. 👇medicilon.com/cases/hengrui-…

#PDXOs are 3D organoid models derived from PDX tumor tissues. At Medicilon, we have successfully developed nine PDXO models encompassing colorectal, pancreatic, gastric, leukemia, and prostate cancers. youtube.com/watch?v=vVUPXE…

#Orthotopic tumor models aim to replicate the clinical setting of tumor growth and progression by implanting these cells or tissues at their anatomically correct or appropriate location within the body of an experimental animal. youtube.com/watch?v=T13A_g…

On September 14, Yayo Biotech received an #FDA IND clinical approval (IND173030) for its independently developed Class 1 innovative drug, #ATR #kinase inhibitor #YY2201 tablets. The approved indication is for the treatment of advanced solid #tumors. medicilon.com/cases/yayo-yy2…

Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (#CNAS). medicilon.com/our-events/cmc…

#Oligonucleotide drugs, as a new class of biomolecular therapeutics, demonstrate significant potential in gene expression regulation through precise targeting of #mRNA. medicilon.com/blog/featured-…

FAQ – Efficient Strategies to Overcome Challenges in Preclinical Bioanalysis of XDC Drugs medicilon.com/blog/featured-…

After 20 years of accumulation, Medicilon boasts 260+ evaluation models for non-tumor diseases, covering the inflammatory & immune diseases, CNS diseases, digestive diseases, , Metabolic diseases, cardiovascular diseases and other diseases. medicilon.com/our-events/non…

Recently, Medicilon officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai). medicilon.com/our-events/gob…

Medicilon leveraged its well-established pharmacokinetics research platform to provide early-stage animal pharmacokinetic services for Fuzerelisib. medicilon.com/cases/genfleet/

Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06 medicilon.com/cases/epimab/

High-Performance Liquid Chromatography (#HPLC) purification technology is a crucial purification technique in the biopharmaceutical industry, used to separate various components in a mixture based on their different chemical properties. medicilon.com/blog/featured-…

Gas Chromatography-Mass Spectrometry (GC-MS) is a commonly used analytical technique that combines the methods of Gas Chromatography (#GC) and Mass Spectrometry (#MS). medicilon.com/blog/featured-…

Recently, Suzhou Jingye Medicine & Chemical Co., Ltd. (Jingye) successfully obtained the "Approval Notice for the Market Launch of Chemical Raw Materials" (Notice No. 2024YS00864) issued by the #NMPA for its gadopentetate chemical raw material.#API #CMC medicilon.com/cases/

Syngeneic tumor models are highly effective in preclinical research for studying cancer biology, assessing therapeutic strategies, and understanding immune responses within a controlled genetic environment. #syngeneicmodels #tumormodels medicilon.com/videos/syngene…

Recently, Medicilon has successfully obtained an invention patent from the National Intellectual Property Administration for its self-developed project titled "Antibodies Targeting Nectin-4 and Their Various Applications"! #antibody